ME/CFS Skeptic
Senior Member (Voting Rights)
The US Food and Drug Administration (FDA) has approved efgartigimod (Vyvgart, argenx), a first-in-class, targeted therapy for adults with generalized myasthenia gravis (gMG) who test positive for the antiacetylcholine receptor (AChR) antibody...
Full text at: https://www.medscape.com/viewarticle/965109
Full text at: https://www.medscape.com/viewarticle/965109